ArticleHepatology (Baltimore, Md.)2026

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Anthony B El-Khoueiry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.